stockrow
Friday 6 November 2026
Export COO’s income statement to Excel — free account
The Cooper Companies, Inc.
COO Healthcare Medical Instruments & Supplies
The Cooper Companies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $4.1 billion, up 5.06% from fiscal 2024.
- Revenue
- +0.56%
- EPS
- +357.1%
- Free cash flow
- +66.0%
- Total debt
- +2.66%
Quarter to July 2026, against a year earlier
63.44
0.98
−1.52%
Follow COO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to October
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jul ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 1,967 | 2,139 | 2,533 | 2,653 | 2,431 | 2,923 | 3,308 | 3,593 | 3,895 | 4,092 | 4,237 | +8.5% | 4,239 | 4,409 | 4,620 | +4.1% | |
| Gross margin, % | 59.65 | 63.85 | 64.45 | 66.21 | 63.14 | 66.92 | 64.67 | 65.62 | 66.64 | 65.54 | 65.93 | +5.9 pt | ||||||
| EBT | 296 | 394 | 332 | 477 | 267 | 492 | 475 | 413 | 582 | 567 | 462 | +7.5% | ||||||
| EBT margin, % | 15.03 | 18.42 | 13.10 | 17.99 | 10.96 | 16.82 | 14.37 | 11.49 | 14.95 | 13.84 | 10.91 | (1.2) pt | ||||||
| Net income | 275 | 373 | 140 | 467 | 238 | 2,945 | 386 | 294 | 392 | 375 | 570 | +3.5% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 10.14 | 10.94 | 12.90 | 13.43 | 12.38 | 14.85 | 16.76 | 18.16 | 19.58 | 20.55 | 21.95 | +8.2% | |||||
| Earnings | 1.40 | 1.88 | 0.70 | 2.33 | 1.20 | 14.79 | 1.94 | 1.48 | 1.96 | 1.87 | 2.93 | +3.3% | ||||||
| Cash flow | 2.63 | 3.03 | 3.41 | 3.61 | 2.48 | 3.75 | 3.51 | 3.07 | 3.57 | 4.00 | 5.35 | +4.8% | ||||||
| Capex | (0.79) | (0.65) | (0.99) | (1.48) | (1.58) | (1.09) | (1.23) | (1.98) | (2.12) | (1.82) | (1.84) | +9.8% | ||||||
| Free cash flow | 1.84 | 2.38 | 2.42 | 2.13 | 0.90 | 2.66 | 2.28 | 1.09 | 1.45 | 2.18 | 3.51 | +1.9% | ||||||
| Book value | 13.90 | 16.24 | 16.84 | 18.36 | 19.47 | 35.27 | 36.35 | 38.16 | 40.64 | 41.38 | 43.15 | +12.9% | ||||||
| Shares, m | 194 | 196 | 196 | 198 | 196 | 197 | 197 | 198 | 199 | 199 | 196 | +0.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 31.49 | 31.95 | 92.92 | 31.16 | 66.64 | 7.12 | 35.23 | 52.75 | 53.68 | 37.19 | 21.65 | 44.0 | |||||
| P/S | 4.34 | 5.49 | 5.01 | 5.42 | 6.47 | 7.10 | 4.08 | 4.29 | 5.35 | 3.40 | 2.89 | 5.1 | ||||||
| P/B | 3.17 | 3.70 | 3.83 | 3.96 | 4.11 | 2.99 | 1.88 | 2.04 | 2.58 | 1.69 | 1.47 | 3.0 | ||||||
| EV/Sales | 4.97 | 6.00 | 5.78 | 6.07 | 7.16 | 7.58 | 4.87 | 4.97 | 5.98 | 3.99 | 3.45 | 5.7 | ||||||
| EV/FCF | 27.37 | 27.52 | 30.78 | 38.26 | 98.84 | 42.25 | 35.78 | 83.13 | 80.86 | 37.62 | 21.58 | 50.2 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 510 | 594 | 669 | 713 | 487 | 739 | 692 | 608 | 709 | 796 | 1,033 | +5.1% | |||||
| Capex | (153) | (127) | (194) | (292) | (310) | (214) | (242) | (392) | (421) | (362) | (355) | +10.1% | ||||||
| Free cash flow | 357 | 466 | 475 | 421 | 176 | 524 | 450 | 215 | 288 | 434 | 678 | +2.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 394 | 557 | 554 | 53 | 270 | 733 | 253 | 736 | 929 | 994 | 415 | +10.8% | |||||
| Net debt | 1,233 | 1,084 | 1,945 | 1,737 | 1,677 | 1,385 | 2,625 | 2,448 | 2,476 | 2,395 | 2,390 | +7.7% | ||||||
| Shareholders’ equity | 2,696 | 3,176 | 3,308 | 3,629 | 3,825 | 6,942 | 7,175 | 7,551 | 8,084 | 8,239 | 8,328 | +13.2% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | 6.13 | 7.99 | 2.55 | 7.54 | 3.66 | 36.03 | 3.66 | 2.54 | 3.27 | 3.03 | 4.55 | (3.1) pt | |||||
| ROIC | 5.16 | 6.30 | 4.80 | 6.37 | 3.54 | 3.80 | 3.24 | 3.33 | 4.18 | 4.01 | 3.17 | (1.2) pt | ||||||
| ROE | 10.20 | 12.70 | 4.32 | 13.46 | 6.40 | 54.70 | 5.47 | 4.00 | 5.02 | 4.59 | 6.84 | (5.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 10,600 | 11,800 | 12,000 | 12,000 | 12,000 | 12,000 | 14,000 | 15,000 | 16,000 | 15,000 | — | +3.9% | |||||
| Revenue/emp, $m | 0.19 | 0.18 | 0.21 | 0.22 | 0.20 | 0.24 | 0.24 | 0.24 | 0.24 | 0.27 | — | +4.4% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Oct 2025 · latest quarter Jul 2026
Business profile
Where the money comes from and where it goes Fiscal 2025
| CooperVision | 2,744 | 67.05% |
|---|---|---|
| CooperSurgical | 1,349 | 32.95% |
| Gross margin | 65.54% | |
| Operating margin | 16.69% | |
| Pre-tax margin | 13.84% |
The Cooper Companies, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SOLV Solventum Corporation | $14.8B | 97.3× | 47.7× | −7.01% (below 0%: shrinking) | n/m | +561.90% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BAX Baxter International Inc. | $13.3B | — (loss-making) | 21.3× | +4.97% (above 0%: growing) | n/m | +255.56% (above 0%: growing) | 33.40% | 7.56% | Compare |
| COO The Cooper Companies, Inc. | $12.1B | 21.7× | 17.5× | +0.56% (above 0%: growing) | +357.14% (above 0%: growing) | +65.96% (above 0%: growing) | 66.77% | 20.82% | |
| ALGN Align Technology, Inc. | $11.3B | 23.1× | 20.4× | +1.92% (above 0%: growing) | +143.87% (above 0%: growing) | +8.26% (above 0%: growing) | 68.73% | 16.67% | Compare |
| RGEN Repligen Corporation | $10.8B | — (loss-making) | — (loss-making) | +10.86% (above 0%: growing) | n/m | −11.46% (below 0%: shrinking) | 53.02% | (14.12%) | Compare |
| AVTR Avantor, Inc. | $10.3B | 30.3× | 34.8× | +4.59% (above 0%: growing) | n/m | −9.03% (below 0%: shrinking) | 31.49% | 8.21% | Compare |
| ATR AptarGroup, Inc. | $9.1B | 34.6× | 25.9× | +6.03% (above 0%: growing) | −73.85% (below 0%: shrinking) | −16.86% (below 0%: shrinking) | 36.59% | 13.25% | Compare |
| BLCO Bausch + Lomb Corporation | $7.1B | — (loss-making) | 749× | +7.34% (above 0%: growing) | n/m | +182.54% (above 0%: growing) | 64.65% | 11.27% | Compare |
| TFX Teleflex Incorporated | $6.5B | — (loss-making) | 37.4× | +28.88% (above 0%: growing) | −17.33% (below 0%: shrinking) | +220.14% (above 0%: growing) | 58.16% | 12.77% | Compare |
| Median of peers | $10.5B | 32.4× | 34.8× | +5.50% | −17.33% | +95.40% | 44.81% | 9.74% |
From the latest earnings call
- Al White said CooperVision’s U.S. revenue outlook reflects channel-inventory reductions, while U.S. consumption continued at a mid-single-digit rate.
- Brian Andrews said the company is expanding commercial investment while targeting $2.2 billion of cumulative free cash flow across fiscal 2026 through 2028.
Largest institutional holders 13F, quarter to 30 June 2026
Held by institutions
107.38%
Held by the ten largest
48.73%
| Holder | Shares | Stake | Change |
|---|---|---|---|
| Vanguard | 23.47m | 12.04% | +25.48k |
| BlackRock | 15.03m | 7.71% | −1.59m |
| T. Rowe Price | 13.01m | 6.67% | −1.44m |
| State Street | 8.89m | 4.56% | +124.22k |
| BROWNING WEST LP | 7.20m | 3.69% | +215.90k |
| UBS | 6.48m | 3.32% | +515.74k |
| KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC | 5.43m | 2.78% | −1.19m |
| Geode Capital Management | 5.36m | 2.75% | +48.29k |
| Franklin Templeton | 5.20m | 2.67% | +206.07k |
| GENERATION INVESTMENT MANAGEMENT LLP | 4.97m | 2.55% | +369.28k |
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.
Pay and ownership Proxy statement filed 24 February 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 16.05m | 1.77m | 67.09 |
| 2024 | 15.43m | 39.83m | 100.46 |
| 2023 | 13.49m | 22.31m | 74.80 |
| 2022 | 11.74m | (9.23m) | 65.59 |
| 2021 | 10.99m | 36.21m | 100.00 |
Ownership
Directors and executive officers, together
2.08%
The Vanguard Group, Inc.100 Vanguard Blvd.Malvern, PA
11.57%
BlackRock, Inc.50 Hudson YardsNew York, NY
7.10%
Capital World Investors333 South Hope Street,
5.50%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement
The Cooper Companies, Inc. (COO) Latest News
29 Oct
27 Oct
24 Sep
23 Sep
18 Sep
14 Sep
COO metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
The Cooper Companies is a medical-device company founded in 1958 and headquartered in San Ramon. Albert G. White III is President and Chief Executive Officer. The company sells products in more than 130 countries through two businesses: CooperVision and CooperSurgical.
CooperVision makes contact lenses for people who need vision correction. Its lenses address ordinary near- and farsightedness as well as astigmatism, presbyopia and myopia. The range includes daily disposable, two-week and monthly lenses, with spherical, toric and multifocal designs. It also sells products for myopia management and specialty eyecare, including orthokeratology and scleral lenses.